OIG Report Tags Biosimilars for Medicare and Beneficiary Savings
Surabhi Dangi-Garimella, Ph.D. Despite biosimilars being around for a while, utilization in the U.S. has not caught on. Several studies have shown the cost benefit of replacing originator or reference products with biosimilars; however, contracts between drug...Read more
